Intravesical CAR T therapy opens door to bladder-sparing cancer treatment

AI Summary

Researchers at Weill Cornell Medicine and partners developed CAR T cells targeting bladder cancer, demonstrating effective tumor control in mice via catheter delivery. This approach could potentially lead to bladder-sparing treatments in humans.

Researchers at Weill Cornell Medicine, Cedars-Sinai Medical Center and Roswell Park Comprehensive Cancer Center have developed genetically engineered CAR T cells that specifically target and kill bladder cancer cells. The study, published in the Journal of Experimental Medicine (JEM), demonstrates that direct delivery of these CAR T cells via a catheter can control bladder tumors in mice, raising hopes that a similar approach may be effective in humans.